This company has been acquired
GRNA Stock Overview
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
GreenLight Biosciences Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$5.90 |
| 52 Week Low | US$0.18 |
| Beta | 1.44 |
| 1 Month Change | 3.20% |
| 3 Month Change | -6.08% |
| 1 Year Change | -85.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.94% |
Recent News & Updates
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Shareholder Returns
| GRNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | -1.9% | -2.8% |
| 1Y | -85.2% | -5.7% | 24.1% |
Return vs Industry: GRNA underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: GRNA underperformed the US Market which returned 13% over the past year.
Price Volatility
| GRNA volatility | |
|---|---|
| GRNA Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GRNA's share price has been volatile over the past 3 months.
Volatility Over Time: GRNA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Andrey Zarur | greenlightbiosciences.com |
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. It provides cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company’s plant and animal health pipeline includes Calantha for the Colorado potato beetle; Varroa mites, an RNA-based syrup that targets reproductive mites; Vegetable Caterpillar Complex, an dsRNA-based pesticide for the Diamond Back Moth; and Spider Mite Complex for the control of Tetranychus urticae.
GreenLight Biosciences Holdings Fundamentals Summary
| GRNA fundamental statistics | |
|---|---|
| Market cap | US$45.43m |
| Earnings (TTM) | -US$157.32m |
| Revenue (TTM) | US$10.34m |
4.4x
P/S Ratio-0.3x
P/E RatioIs GRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRNA income statement (TTM) | |
|---|---|
| Revenue | US$10.34m |
| Cost of Revenue | US$129.70m |
| Gross Profit | -US$119.35m |
| Other Expenses | US$37.96m |
| Earnings | -US$157.32m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | -1,153.96% |
| Net Profit Margin | -1,521.00% |
| Debt/Equity Ratio | 111.6% |
How did GRNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/25 08:55 |
| End of Day Share Price | 2023/07/21 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GreenLight Biosciences Holdings is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Burleson | Canaccord Genuity |
| John Ezekiel Roberts | Credit Suisse |